Shi Liqiang, Li Chengqiang, Bai Yaya, Cao Yuqin, Zhao Shengguang, Chen Xiaoyan, Cheng Zenghui, Zhang Yajie, Li Hecheng
Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China.
Eur Radiol. 2025 Mar;35(3):1594-1604. doi: 10.1007/s00330-024-11141-4. Epub 2024 Oct 29.
To develop and validate a CT-based radiomics model to predict pathologic complete response (pCR) after neoadjuvant immunotherapy plus chemoradiotherapy (NICRT) in locally advanced esophageal squamous cell carcinoma (ESCC).
A total of 105 patients with locally advanced ESCC receiving NICRT from February 2019 to December 2023 were enrolled. Patients were randomly divided into the training cohort and the test cohort at a 3:1 ratio. Enhanced CT scans were obtained before NICRT treatment. The 2D and 3D regions of interest were segmented, and features were extracted, followed by feature selection. Six algorithms were applied to construct the radiomics and clinical models. These models were evaluated by area under curve (AUC), accuracy, sensitivity, and specificity, and their respective optimal algorithms were further compared.
Forty-eight patients (45.75%) achieved pCR after NICRT. The AUC values of three algorithms in 2D radiomics models were higher than those in the 3D radiomics model and clinical model. Among these, the 2D radiomics model based on eXtreme Gradient Boosting (XGBoost) exhibited the best performance, with an AUC of 0.89 (95% CI, 0.81-0.97), accuracy of 0.85, sensitivity of 0.86, and specificity of 0.84 in the training cohort, and an AUC of 0.80 (95% CI, 0.64-0.97), accuracy of 0.77, sensitivity of 0.84, and specificity of 0.69 in the test cohort. Calibration curves also showed good agreement between predicted and actual response, and the decision curve analysis further confirmed its clinical applicability.
The 2D radiomics model can effectively predict pCR to NICRT in locally advanced ESCC.
Question Can CT-based radiomics predict pathologic complete response (pCR) after neoadjuvant immunotherapy plus chemoradiotherapy (NICRT) in locally advanced esophageal squamous cell carcinoma (ESCC)? Findings The model based on eXtreme Gradient Boosting (XGBoost) performed best, with an AUC of 0.89 in the training and 0.80 in the test cohort. Clinical relevance This CT-based radiomics model exhibits promising performance for predicting pCR to NICRT in locally advanced ESCC, which may be valuable in personalized treatment plan optimization.
建立并验证基于CT的放射组学模型,以预测局部晚期食管鳞状细胞癌(ESCC)新辅助免疫治疗联合放化疗(NICRT)后的病理完全缓解(pCR)。
纳入2019年2月至2023年12月期间接受NICRT的105例局部晚期ESCC患者。患者按3:1的比例随机分为训练队列和测试队列。在NICRT治疗前进行增强CT扫描。分割二维和三维感兴趣区域,提取特征,然后进行特征选择。应用六种算法构建放射组学和临床模型。通过曲线下面积(AUC)、准确性、敏感性和特异性对这些模型进行评估,并进一步比较它们各自的最佳算法。
48例患者(45.75%)在NICRT后达到pCR。二维放射组学模型中三种算法的AUC值高于三维放射组学模型和临床模型。其中,基于极端梯度提升(XGBoost)的二维放射组学模型表现最佳,训练队列中的AUC为0.89(95%CI,0.81-0.97),准确性为0.85,敏感性为0.86,特异性为0.84;测试队列中的AUC为0.80(95%CI,0.64-0.97),准确性为0.77,敏感性为0.84,特异性为0.69。校准曲线也显示预测反应与实际反应之间具有良好的一致性,决策曲线分析进一步证实了其临床适用性。
二维放射组学模型可有效预测局部晚期ESCC对NICRT的pCR。
问题基于CT的放射组学能否预测局部晚期食管鳞状细胞癌(ESCC)新辅助免疫治疗联合放化疗(NICRT)后的病理完全缓解(pCR)?发现基于极端梯度提升(XGBoost)的模型表现最佳,训练队列中的AUC为0.89,测试队列中的AUC为0.80。临床意义这种基于CT的放射组学模型在预测局部晚期ESCC对NICRT的pCR方面表现出良好的性能,这可能对个性化治疗方案优化有价值。